Barinthus Biotherapeutics (BRNS) Projected to Announce Quarterly Earnings on Thursday

Barinthus Biotherapeutics (NASDAQ:BRNS) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Barinthus Biotherapeutics to announce earnings of ($0.28) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Barinthus Biotherapeutics Trading Up 7.5%

Barinthus Biotherapeutics stock opened at $0.60 on Tuesday. The firm has a 50-day moving average of $0.65 and a 200-day moving average of $0.65. The firm has a market cap of $24.51 million, a P/E ratio of -0.47 and a beta of -0.39. Barinthus Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $1.83.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.